Posted by Michael Wonder on 13 Dec 2025
GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older
12 December 2025 - GSK today announced that the EMA's CHMP has recommended expanding the indication of its adjuvanted recombinant respiratory syncytial virus vaccine to all adults aged 18 years and older.
The European Commission’s final decision is expected in February 2026.
If approved, the expanded indication would make the vaccine available for all adults aged 18 years and older.
